Amgenの機関の所有権
Amgenの機関の所有権は何ですか。
Amgen, Inc.の機関の所有権は81.50%です。
機関の所有権の定義は何ですか。
機関所有権は、ミューチュアル・ファンドまたは年金基金、保険会社、投資会社、その他の資金を管理する他の団体が所有する会社の株式数です。
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
XETRAのセクタHealth Careにおける機関の所有権の企業と比べるAmgen
Amgenは何をしますか。
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Amgenと類似の機関の所有権
- MaxCyteの機関の所有権は81.43%です。
- City Office REIT Incの機関の所有権は81.45%です。
- AGCOの機関の所有権は81.47%です。
- Kemperの機関の所有権は81.47%です。
- LL Flooring Incの機関の所有権は81.48%です。
- Gamma Communications Plcの機関の所有権は81.49%です。
- Amgenの機関の所有権は81.50%です。
- Marinus Pharmaceuticals Incの機関の所有権は81.50%です。
- Automatic Data Processingの機関の所有権は81.52%です。
- Janus Henderson plcの機関の所有権は81.52%です。
- Fidelity National Incの機関の所有権は81.53%です。
- Iron Mountainの機関の所有権は81.53%です。
- Okta Incの機関の所有権は81.53%です。